STERIS plc

NYSE:STE Voorraadrapport

Marktkapitalisatie: US$21.3b

STERIS Beheer

Beheer criteriumcontroles 3/4

De CEO STERIS is Dan Carestio, benoemd in Jul2021, heeft een ambtstermijn van 3.33 jaar. De totale jaarlijkse vergoeding van { bedraagt $ 9.55M, bestaande uit 10.8% salaris en 89.2% bonussen, inclusief aandelen en opties van het bedrijf. bezit rechtstreeks 0.057% van de aandelen van het bedrijf, ter waarde $ 12.12M. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 4.8 jaar en 7.8 jaar.

Belangrijke informatie

Dan Carestio

Algemeen directeur

US$9.6m

Totale compensatie

Percentage CEO-salaris10.8%
Dienstverband CEO3.3yrs
Eigendom CEO0.06%
Management gemiddelde ambtstermijn4.8yrs
Gemiddelde ambtstermijn bestuur7.8yrs

Recente managementupdates

Recent updates

What Does STERIS plc's (NYSE:STE) Share Price Indicate?

Oct 19
What Does STERIS plc's (NYSE:STE) Share Price Indicate?

Is STERIS (NYSE:STE) A Risky Investment?

Oct 01
Is STERIS (NYSE:STE) A Risky Investment?

Steris: Dental Divestiture, Surgical Instrumentation Acquisition, But Overvalued

Sep 16

Earnings Tell The Story For STERIS plc (NYSE:STE)

Sep 13
Earnings Tell The Story For STERIS plc (NYSE:STE)

Steris: Q2 Numbers Solidify Buy Thesis

Aug 13

STERIS plc's (NYSE:STE) Intrinsic Value Is Potentially 59% Above Its Share Price

Aug 08
STERIS plc's (NYSE:STE) Intrinsic Value Is Potentially 59% Above Its Share Price

When Should You Buy STERIS plc (NYSE:STE)?

Jul 04
When Should You Buy STERIS plc (NYSE:STE)?

Is STERIS (NYSE:STE) Using Too Much Debt?

Jun 13
Is STERIS (NYSE:STE) Using Too Much Debt?

Steris: Moving On, Losing Its Teeth

Apr 14

STERIS plc's (NYSE:STE) Intrinsic Value Is Potentially 31% Above Its Share Price

Mar 29
STERIS plc's (NYSE:STE) Intrinsic Value Is Potentially 31% Above Its Share Price

STERIS (NYSE:STE) Has A Pretty Healthy Balance Sheet

Mar 07
STERIS (NYSE:STE) Has A Pretty Healthy Balance Sheet

Steris: Strong Healthcare Products Growth Coupled With Weak AST Business

Feb 17

STERIS plc's (NYSE:STE) Business Is Trailing The Industry But Its Shares Aren't

Feb 15
STERIS plc's (NYSE:STE) Business Is Trailing The Industry But Its Shares Aren't

An Intrinsic Calculation For STERIS plc (NYSE:STE) Suggests It's 23% Undervalued

Dec 17
An Intrinsic Calculation For STERIS plc (NYSE:STE) Suggests It's 23% Undervalued

Should You Investigate STERIS plc (NYSE:STE) At US$203?

Nov 24
Should You Investigate STERIS plc (NYSE:STE) At US$203?

Steris: Comprehensive Sterilization Portfolios Tailored To Procedure Volumes

Nov 08

We Think STERIS (NYSE:STE) Can Stay On Top Of Its Debt

Nov 06
We Think STERIS (NYSE:STE) Can Stay On Top Of Its Debt

Are STERIS plc (NYSE:STE) Investors Paying Above The Intrinsic Value?

Sep 18
Are STERIS plc (NYSE:STE) Investors Paying Above The Intrinsic Value?

Steris: Remains On Track For Strong Fiscal '24, Added Upsides From Operating Leverage

Sep 01

When Should You Buy STERIS plc (NYSE:STE)?

Aug 10
When Should You Buy STERIS plc (NYSE:STE)?

Steris: Continuing To Grow The Product Lineup

Jun 20

Steris falls 10% on Q3 revenue, profit miss, 2023 profit guidance lowered

Feb 09

Steris declares $0.47 dividend

Feb 01

These 4 Measures Indicate That STERIS (NYSE:STE) Is Using Debt Reasonably Well

Feb 01
These 4 Measures Indicate That STERIS (NYSE:STE) Is Using Debt Reasonably Well

Calculating The Intrinsic Value Of STERIS plc (NYSE:STE)

Dec 28
Calculating The Intrinsic Value Of STERIS plc (NYSE:STE)

Steris declares $0.47 dividend

Nov 02

STERIS (NYSE:STE) Seems To Use Debt Quite Sensibly

Nov 01
STERIS (NYSE:STE) Seems To Use Debt Quite Sensibly

Steris: Non-GAAP Valuations Supportive Of Substantial Upside

Sep 04

STERIS (NYSE:STE) Will Pay A Larger Dividend Than Last Year At $0.47

Aug 18
STERIS (NYSE:STE) Will Pay A Larger Dividend Than Last Year At $0.47

STERIS' (NYSE:STE) Dividend Will Be Increased To $0.47

Aug 04
STERIS' (NYSE:STE) Dividend Will Be Increased To $0.47

Steris Non-GAAP EPS of $1.90 in-line, revenue of $1.2B misses by $20M

Aug 02

Analyse CEO-vergoeding

Hoe is Dan Carestio's beloning veranderd ten opzichte van STERIS's winst?
DatumTotale vergoedingSalarisBedrijfswinsten
Sep 30 2024n/an/a

US$591m

Jun 30 2024n/an/a

US$561m

Mar 31 2024US$10mUS$1m

US$551m

Dec 31 2023n/an/a

US$1b

Sep 30 2023n/an/a

US$1b

Jun 30 2023n/an/a

US$576m

Mar 31 2023US$8mUS$970k

US$557m

Dec 31 2022n/an/a

-US$28m

Sep 30 2022n/an/a

-US$8m

Jun 30 2022n/an/a

US$377m

Mar 31 2022US$6mUS$767k

US$285m

Dec 31 2021n/an/a

US$279m

Sep 30 2021n/an/a

US$250m

Jun 30 2021n/an/a

US$286m

Mar 31 2021US$3mUS$542k

US$397m

Dec 31 2020n/an/a

US$433m

Sep 30 2020n/an/a

US$424m

Jun 30 2020n/an/a

US$413m

Mar 31 2020US$2mUS$522k

US$408m

Dec 31 2019n/an/a

US$393m

Sep 30 2019n/an/a

US$336m

Jun 30 2019n/an/a

US$319m

Mar 31 2019US$2mUS$482k

US$304m

Dec 31 2018n/an/a

US$269m

Sep 30 2018n/an/a

US$316m

Jun 30 2018n/an/a

US$303m

Mar 31 2018US$1mUS$379k

US$291m

Compensatie versus markt: De totale vergoeding ($USD 9.55M ) Dan } is ongeveer het gemiddelde voor bedrijven van vergelijkbare omvang in de US markt ($USD 12.73M ).

Compensatie versus inkomsten: De beloning van Dan is het afgelopen jaar met meer dan 20% gestegen, terwijl de winst van het bedrijf met meer dan 20% is gedaald.

CEO

Dan Carestio (51 yo)

3.3yrs

Tenure

US$9,550,776

Compensatie

Mr. Daniel A. Carestio, also known as Dan, serves as the Chief Executive Officer & President at STERIS plc since July 29, 2021. He had been Senior Vice President and Chief Operating Officer at STERIS plc s...

Leiderschapsteam

NaamPositieTenureCompensatieEigendom
Daniel Carestio
President3.3yrsUS$9.55m0.057%
$ 12.1m
Michael Tokich
Senior VP & CFO16.7yrsUS$3.24m0.047%
$ 10.0m
John Zangerle
Senior VP11.3yrsUS$2.63m0.034%
$ 7.2m
Mary Fraser
SVP & Chief Human Resources Officer4.3yrsUS$1.85m0.011%
$ 2.4m
Cary Majors
Senior VP & President of Healthcare5.3yrsUS$2.15m0.013%
$ 2.8m
Karen Burton
VP & Chief Accounting Officer7.8yrsgeen gegevens0.0044%
$ 940.2k
Julie Winter
Vice President of Investor Relations & Corporate Communicationsno datageen gegevensgeen gegevens
Julia Madsen
Senior VP & GM of Life Sciences4.3yrsgeen gegevens0.0095%
$ 2.0m
Andrew Xilas
Senior VP & GM of Dental3.4yrsUS$1.92m0.0064%
$ 1.4m
Kenneth Kohler
Senior VP & GM of ASTno datageen gegevens0.0035%
$ 750.9k
Renato Tamaro
VP & Corporate Treasurer7.3yrsgeen gegevens0.0069%
$ 1.5m
Walter Rosebrough
CEO Emeritus & Senior Advisor3.3yrsUS$1.16mgeen gegevens

4.8yrs

Gemiddelde duur

56yo

Gemiddelde leeftijd

Ervaren management: Het managementteam van STE wordt beschouwd als ervaren (gemiddelde ambtstermijn 4.8 jaar).

Bestuursleden

NaamPositieTenureCompensatieEigendom
Daniel Carestio
President3.8yrsUS$9.55m0.057%
$ 12.1m
Richard Breeden
Independent Director16.6yrsUS$353.94k0.033%
$ 7.0m
Mohsen Sohi
Independent Chairman of the Board19.3yrsUS$503.73k0.023%
$ 4.8m
Jacqueline Kosecoff
Independent Director21.1yrsUS$348.93k0.027%
$ 5.7m
Cynthia Feldmann
Independent Director19.7yrsUS$349.84k0.0095%
$ 2.0m
Richard Steeves
Independent Director9yrsUS$349.96k0%
$ 0
Paul Martin
Independent Director3.5yrsUS$342.28kgeen gegevens
Nirav Shah
Independent Director6.5yrsUS$336.34k0.00030%
$ 63.8k
Christopher Holland
Independent Director4.3yrsUS$342.34k0.00059%
$ 125.5k
Esther Alegria
Independent Director1.5yrsUS$408.96kgeen gegevens

7.8yrs

Gemiddelde duur

65.5yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van STE wordt beschouwd als ervaren (gemiddelde ambtstermijn 7.8 jaar).